Clinical cell analyzer reagents for facslyrics medical device
Ended Awarded Last action
- Contract number
- HT001425FE018
- Awardee
-
Becton, Dickinson And Company UEI MM5ZHL8SRFY5 Part of Becton, Dickinson And Co
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $16,655
Award facts
- Contract value 100% obligated
- $16,655.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20814, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $16,655 |
About this award
Becton, Dickinson and Company's BD Biosciences division was awarded a $16,655.20 firm fixed-price call against a blanket purchase agreement by the Defense Health Agency for clinical cell analyzer reagents supporting the FACSLyric medical device. The contract was awarded on September 18, 2025, with an ultimate completion date of September 17, 2026, and will be performed in Bethesda, Maryland. This award represents a task order under BD Biosciences' established BPA with the Defense Health Agency, which maintains a $4 million indefinite delivery vehicle through September 2030 for specialized laboratory reagents supporting military medical research and healthcare delivery across the Department of Defense enterprise. No small business set-aside was applied to this award.
BD Biosciences holds an established position as a critical supplier of flow cytometry systems and associated consumables to federal healthcare and research agencies. The FACSLyric platform is a key component of BD's flow cytometry instrument portfolio supplied to federal customers for biomedical research and clinical diagnostics. This contract enables the Defense Health Agency to procure necessary reagent supplies to maintain operational capability of existing FACSLyric instrumentation across military treatment centers and research facilities, supporting the agency's clinical laboratory and immunological research missions without requiring competitive re-solicitation under the existing BPA framework.
Quick answers
Who was awarded contract HT001425FE018?
HT001425FE018 was awarded to Becton, Dickinson And Company by Defense Health Agency (Department of Defense) on September 18, 2025.
How much is contract HT001425FE018 worth?
The government has obligated $16,655 on HT001425FE018.
Is contract HT001425FE018 an order under another contract?
Yes. HT001425FE018 is a BPA call under HT001425AE005, a blanket purchase agreement.
Was contract HT001425FE018 competed?
The extent of competition for HT001425FE018 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award